2025
International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma.
Abou-Alfa G, Yen Y, Harding J, Whang-Peng J, Shi Y, Yuen M, Li X, Gu S, Liu C, Jeng L, Yen C, Pan C, Chen S, Hsieh J, Saif M, Liu S, Li F, Lam W, Chu E, Cheng Y. International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16244.Peer-Reviewed Original ResearchProgression-free survivalPer-protocol setPlacebo armYIV-906Child-Pugh A liver functionMulti-targeted tyrosine kinase inhibitorRandomized phase 2 studyTumor rejection in vivoRandomized placebo-controlled studyRisk of disease progressionTumor microenvironment inflammationAdvanced hepatocellular carcinomaECOG performance statusPlacebo-controlled studyPhase 2 studyTyrosine kinase inhibitorsRejection in vivoCohort of patientsPotential clinical benefitCTCAE versionTolerated sorafenibSorafenib monotherapyDouble-blindPlacebo-ControlledITT group
2024
Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.
Ravani L, Calomeni P, Vilbert M, Madeira T, Wang M, Deng D, Testa L, Clifton K, Wander S, Lustberg M. Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis. Journal Of Clinical Oncology 2024, 42: 1065-1065. DOI: 10.1200/jco.2024.42.16_suppl.1065.Peer-Reviewed Original ResearchProgression-free survivalRandomized Controlled TrialsEndocrine therapyOverall survivalET monotherapyDisease progressionHormone receptor-positive/human epidermal growth factor receptor 2-negativeAssociated with longer progression-free survivalHormone receptor-positive metastatic breast cancerPooled analysisPooling of randomized controlled trialsCohort studyCyclin-dependent kinase 4/6 inhibitorsLonger progression-free survivalProgression-free survival benefitCDK4/6 inhibitor therapyIndividual-patient data meta-analysisMetastatic breast cancerPhase III trialsMeta-analysisStandard-of-careObservational cohort studyPotential clinical benefitIndividual patient dataPatient data
2023
EFFICACY AND SAFETY OF HYPERBARIC OXYGEN THERAPY IN FISTULIZING CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Dokmak A, Sweigart B, Orekondy N, Jangi S, Hamdeh S, Weinstock J, Kochar G, Shen B, Levy A. EFFICACY AND SAFETY OF HYPERBARIC OXYGEN THERAPY IN FISTULIZING CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Inflammatory Bowel Diseases 2023, 29: s63-s63. DOI: 10.1093/ibd/izac247.121.Peer-Reviewed Original ResearchHyperbaric oxygen therapy sessionsHyperbaric oxygen therapyInflammatory bowel diseaseClinical responseClinical remissionRandomized Controlled TrialsPartial responseRectovaginal fistulaFistulizing CDResponse to HBOTCrohn's diseaseControlled TrialsLow adverse event ratesSystematic reviewClinical response rateOutcome dataFistulizing Crohn's diseaseAdjunctive hyperbaric oxygen therapyClosure of fistulaMeta-analysisCochrane Library databasesAdverse event ratesCessation of drainagePotential clinical benefitCase-control study
2022
Impact of early detection on cancer curability: A modified Delphi panel study
Schwartzberg L, Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk B, Wong D, Campos C, Yermilov I. Impact of early detection on cancer curability: A modified Delphi panel study. PLOS ONE 2022, 17: e0279227. PMID: 36542647, PMCID: PMC9770338, DOI: 10.1371/journal.pone.0279227.Peer-Reviewed Original ResearchConceptsBlood testsLikelihood of benefitCancer typesEarly detectionEarly cancer detectionSolid tumorsTotal cancer incidenceAmerican Joint CommitteeLow cure rateRAND/UCLAPotential clinical benefitCancer detectionDelphi panel studyLong cancerClinical benefitCure ratePotential benefitsCancer curabilityMost cancer typesCancer incidenceHigh curabilityJoint CommitteeTreat cancersExpert consensusPanel consensusImproving Population Access to Stroke Expertise Via Telestroke: Hospitals to Target and the Potential Clinical Benefit
Richard J, Mehrotra A, Schwamm L, Wilcock A, Uscher‐Pines L, Majersik J, Zachrison K. Improving Population Access to Stroke Expertise Via Telestroke: Hospitals to Target and the Potential Clinical Benefit. Journal Of The American Heart Association 2022, 11: e025559. PMID: 35435016, PMCID: PMC9238444, DOI: 10.1161/jaha.122.025559.Peer-Reviewed Original Research
2020
A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).
Harding J, Abou-Alfa G, Shi Y, Whang-Peng J, Yuen M, Saif W, Tian A, Gu S, Lam W, Liu S, Cheng Y, Chu E, Yen Y. A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2020, 38: tps601-tps601. DOI: 10.1200/jco.2020.38.4_suppl.tps601.Peer-Reviewed Original ResearchProgression-free survivalHepatocellular carcinomaPrimary endpointControl armFirst-line systemic treatment optionMedian progression-free survivalTreatment-related adverse eventsCTCAE version 4.0Prior systemic therapyChronic HBV infectionDisease control rateECOG performance statusObjective response ratePlacebo-controlled studySystemic treatment optionsPhase 2 studyRate of gradeKey eligibility criteriaAdvanced hepatocellular carcinomaPotential clinical benefitTyrosine kinase inhibitorsActivation/proliferationQuality of lifeTraditional Chinese medicineAdvanced disease
2019
End-of-Treatment Intracerebral and Ventricular Hemorrhage Volume Predicts Outcome
de Havenon A, Joyce E, Yaghi S, Ansari S, Delic A, Taussky P, Alexander M, Tirschwell D, Grandhi R. End-of-Treatment Intracerebral and Ventricular Hemorrhage Volume Predicts Outcome. Stroke 2019, 51: 652-654. PMID: 31842688, PMCID: PMC7000178, DOI: 10.1161/strokeaha.119.028199.Peer-Reviewed Original ResearchConceptsIntraventricular hemorrhage volumeIntracerebral hemorrhageClot evacuationHemorrhage volumeBetter outcomesVolume scoreInvasive clot evacuationMISTIE III trialSurgical clot evacuationGood neurological outcomePotential clinical benefitNeurological outcomeIII trialsPrimary outcomeClinical benefitHematoma volumePoor outcomeFunctional outcomeSurgical armICH sizeTherapeutic planningSecondary analysisPatientsStrong associationStratification scaleExploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
Walters M, Tisdale J, Kwiatkowski J, Krishnamurti L, Mapara M, Schmidt M, Miller A, Pierciey F, Huang W, Ribeil J, Kanter J, Thompson A. Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy. Blood 2019, 134: 2061. DOI: 10.1182/blood-2019-128814.Peer-Reviewed Original ResearchAcute chest syndromeVaso-occlusive crisisGroup A patientsRate of VOCAdverse eventsA patientsPatient 1Group AClinical benefitLast visitBluebird BioHematopoietic stem cellsInitial patientsPatient 2Busulfan conditioningGroup BHbF levelsVeno-occlusive liver diseaseRed blood cell transfusionFull hematological recoveryBlood cell transfusionCases of gradeLentiviral vectorsGene therapyPotential clinical benefit
2016
Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial
Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, Ostwaldt AC, del Zoppo GJ, Simard JM, Jacobson S, Kimberly WT. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology 2016, 15: 1160-1169. PMID: 27567243, DOI: 10.1016/s1474-4422(16)30196-x.Peer-Reviewed Original ResearchConceptsPlacebo-controlled phase 2 trialIntravenous glyburideLarge hemispheric infarctionPhase 2 trialGlyburide groupHemispheric infarctionDecompressive craniectomyPlacebo groupBrain swellingModified Rankin Scale scoreProtocol study populationWeb-based randomisationComposite primary outcomePrimary efficacy outcomeSerious adverse eventsProportion of patientsRankin Scale scoreBolus intravenous injectionLarge hemispheric strokePotential clinical benefitEfficacy outcomesStudy drugAdverse eventsCardiac eventsCerebral edema
2012
Dynamic modulated brachytherapy (DMBT) for rectal cancer
Webster M, Devic S, Vuong T, Han D, Park J, Scanderbeg D, Lawson J, Song B, Watkins W, Pawlicki T, Song W. Dynamic modulated brachytherapy (DMBT) for rectal cancer. Medical Physics 2012, 40: 011718. PMID: 23298088, DOI: 10.1118/1.4769416.Peer-Reviewed Original ResearchConceptsRate brachytherapyDose heterogeneity indexTreatment deliveryAverage clinical target volumeClinical target volumePotential clinical benefitPlan qualityTotal treatment timeTreatment planning simulationClinical treatment plansRectal cancerClinical benefitMean dosePrescription doseTreatment planTumor coverageTarget volumeClinical patient casesBrachytherapyPatient casesDose conformalityDoseRectal cavityCritical structuresHigh-quality plans
2008
Developmental Regulation of NO-Mediated VEGF-Induced Effects in the Lung
Bhandari V, Choo-Wing R, Lee CG, Yusuf K, Nedrelow JH, Ambalavanan N, Malkus H, Homer RJ, Elias JA. Developmental Regulation of NO-Mediated VEGF-Induced Effects in the Lung. American Journal Of Respiratory Cell And Molecular Biology 2008, 39: 420-430. PMID: 18441284, PMCID: PMC2551703, DOI: 10.1165/rcmb.2007-0024oc.Peer-Reviewed Original ResearchMeSH KeywordsAmniotic FluidAnimalsAnimals, NewbornBronchopulmonary DysplasiaCapillary PermeabilityFemaleHemorrhageHumansHyperoxiaInfant, NewbornLungLung DiseasesMiceMice, TransgenicNitric OxidePregnancyPulmonary SurfactantsRespiratory Distress Syndrome, NewbornTracheaVascular Endothelial Growth Factor AConceptsVascular endothelial growth factorVEGF levelsLung developmentNitric oxide mediationNO-dependent mechanismAdult murine lungPotential clinical benefitTransgenic murine modelSignificant differencesEndothelial growth factorBronchopulmonary dysplasiaLung injuryPulmonary hemorrhageCytokine responsesClinical benefitNeonatal lungHuman neonatesMurine modelMurine lungMature lungLungPathologic conditionsAdult lungSurfactant phospholipidsExtravascular effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply